Creative Medical Technology Holdings secured approximately $4.5 million in gross proceeds through agreements for the exercise of existing warrants. The financing involves the immediate exercise of outstanding warrants to purchase up to 2,790,340 shares of common stock originally issued in October 2025, at a reduced exercise price of $1.60 per share, along with the purchase of 5,580,680 shares of common stock at the same price. Investors received new five-year warrants exercisable immediately upon issuance. H.C. Wainwright & Co. acted as exclusive placement agent for the transaction, which is expected to close on June 30, 2026, subject to customary conditions. The company plans to use the net proceeds for working capital and general corporate purposes to advance its regenerative medicine and immunotherapy pipeline.
Creative Medical Technology Holdings IncCompany raised $4.5M through warrant exercises, providing working capital for pipeline advancement.